Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

December 15, 2023

https://www.globenewswire.com/news-release/2023/11/13/2778893/0/en/Akero-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html

— Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 —

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates.

Read more at globenewswire.com

Related news for (AKRO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.